Despite the same CCR5 target;...in vitro susceptibility to Leronlima is NOT affected by extensiive drug resistance and exposure to Miraviroc;...
Leronlimab may have some Advantages over FDA Approved Miraviroc as a clinically valuable CCR5 antagonist,... including LOWER toxicity,... less Drug-Drug INTERACTION issues and LESS frequent dosing... Leronlimab can play a key role in subjects with VERY limited therapeutic options and CCR5-tropic virus.